File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Metastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody

TitleMetastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody
Authors
Issue Date2012
PublisherScientific Research Publishing, Inc. The Journal's web site is located at http://www.scirp.org/journal/jct/
Citation
Journal of Cancer Therapy, 2012, v. 3 n. 6A, p. 902-911 How to Cite?
AbstractColorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses.
Persistent Identifierhttp://hdl.handle.net/10722/180140
ISSN

 

DC FieldValueLanguage
dc.contributor.authorLam, KO-
dc.contributor.authorLee, VHF-
dc.date.accessioned2013-01-21T01:29:55Z-
dc.date.available2013-01-21T01:29:55Z-
dc.date.issued2012-
dc.identifier.citationJournal of Cancer Therapy, 2012, v. 3 n. 6A, p. 902-911-
dc.identifier.issn2151-1934-
dc.identifier.urihttp://hdl.handle.net/10722/180140-
dc.description.abstractColorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses.-
dc.languageeng-
dc.publisherScientific Research Publishing, Inc. The Journal's web site is located at http://www.scirp.org/journal/jct/-
dc.relation.ispartofJournal of Cancer Therapy-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleMetastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody-
dc.typeArticle-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityLee, VHF=rp00264-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.4236/jct.2012.326116-
dc.identifier.hkuros212956-
dc.identifier.volume3-
dc.identifier.issue6A-
dc.identifier.spage902-
dc.identifier.epage911-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats